Eric Winer, MD, began his tenure at Yale in February 2022 with a vision to expand the cancer program and national prominence of Yale Cancer Center and Smilow Cancer Hospital. He is already recruiting more physicians and researchers and focusing on healthcare inequities in Connecticut.
Scientists at Yale Cancer Center have found that patients with breast cancer and high levels of insulin in the blood may be responsive to metabolism-targeting treatments, which in turn may improve the effectiveness of subsequent chemotherapy treatments.
In a study led by Dr. Lajos Pusztai, Professor of Medicine (Medical Oncology) at Yale Cancer Center, researchers across various institutions, and on behalf of the I-SPY consortium, developed a novel continuous residual cancer based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in preoperative breast cancer trials.
New research from Yale Cancer Center provides a new understanding of patients’ views of artificial intelligence (AI) in health care. W
The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
African-American adult patients are more likely than white patients to receive substandard gastrointestinal cancer surgery, according a large study led by researchers at Yale Cancer Center. The findings are reported today in the journal JAMA Network Open.
An analysis by Yale Cancer Center researchers identified accelerated genetic aging in breast tissue adjacent to breast cancer tumors. Their findings demonstate that adjacent breast tissue is “biologically older” than the chronologic age of the patient, a discovery that may explain why some women develop breast cancer at younger age and may also become a future marker of breast cancer risk.
Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma.
The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.
Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) not eligible for cisplatin chemotherapy.
A new study led by researchers at Yale Cancer Center and the University of Maryland shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.
Researchers at the Yale Cancer Biology Institute have clarified the role of a recurring cancer-associated tumor mutation in glioblastoma multiforme (GBM), the most common and most aggressive type of malignant brain tumor. The findings were published in Nature.
A new study by researchers at Yale Cancer Center shows using current standard human epidermal growth factor receptor 2 (HER2) assays as a diagnostic test may result in a mis-assignment of patients for treatment for breast cancer with a promising new drug.
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat.
Ian E. Krop, MD, PhD, has been appointed Chief Clinical Research Officer, Associate Cancer Center Director for Clinical Research, and Director of the Yale Cancer Center Clinical Trials Office.
Smilow Cancer Hospital expert has the latest recommendations for patients and families.
Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers. These findings may offer insights into novel therapeutic strategies to treat patients with COVID-19 related blood clots. The findings were reported today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right